Over 295 Companies Advance Novel Therapies for B-cell Lymphoma
More than 295 pharmaceutical companies, including major players, are progressing in the development of B-cell lymphoma treatments, with several candidates already in Phase III clinical trials.
Over 295 pharmaceutical companies are developing new therapies for B-cell lymphoma, according to a report by market analysis firm DelveInsight. The report, which covers the global B-cell lymphoma therapeutic development landscape, highlights a significant number of new drug candidates across various stages of clinical trials.
The study identifies more than 295 companies, including prominent players such as Bristol Myers Squibb, Roche, Nektar Therapeutics, and Miltenyi Biotec. Several therapies, like Bristol Myers Squibb's Lisocabtagene maraleucel, have advanced to Phase III of clinical evaluation, signaling substantial progress in the field.
The report provides a detailed insight into the development of B-cell lymphoma treatments, encompassing both clinical and non-clinical products. The analysis includes assessments based on product type, clinical stage, route of administration, and molecule type, along with information on inactive or discontinued development projects.
Recent clinical trials, such as Janssen's study of prizloncabtagene autoleucel and Genmab's trials for epcoritamab, demonstrate ongoing activity. Roche and Merck Sharp & Dohme have also announced new Phase III studies evaluating combination therapies for DLBCL patients.
B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and the development of effective treatments remains critical. DelveInsight's report offers a comprehensive overview of the ongoing research and future outlook in this rapidly evolving medical sector.